18F-radiopharmacokinetics of [18F]-5-fluorouracil in a mouse bearing two colon tumors with a different 5-fluorouracil sensitivity: A study for a correlation with oncological results

Nuclear Medicine and Biology

Volumn 23, Issue 3, 1996, Pages 333-342

  Visser, Gerard W M ^a   Van Der Wilt, Clasina L ^b   Wedzinga, Rinny ^a   Peters, Godefridus J ^b   Herscheid, Jacobus D M ^a  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

5 Fluorouracil sensitivity; 18F Radiopharmacokinetics; Colon carcinoma; 18F 5 Fluorouracil

Indexed keywords

FLUORINE 18; FLUOROURACIL 18; UNCLASSIFIED DRUG; FLOXURIDINE PHOSPHATE; FLUORINE; FLUOROURACIL; THYMIDYLATE SYNTHASE;

ANIMAL EXPERIMENT; ARTICLE; CANCER GRAFT; COLON TUMOR; CONTROLLED STUDY; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; PHARMACOKINETICS; ANIMAL; BAGG ALBINO MOUSE; BLOOD; CELL LINE; FEMALE; ISOTOPE LABELING; KINETICS; METABOLISM; METHODOLOGY; TISSUE DISTRIBUTION;

ANIMALS; CELL LINE; COLONIC NEOPLASMS; FEMALE; FLUORINE RADIOISOTOPES; FLUORODEOXYURIDYLATE; FLUOROURACIL; ISOTOPE LABELING; KINETICS; MICE; MICE, INBRED BALB C; THYMIDYLATE SYNTHASE; TISSUE DISTRIBUTION;

EID: 0029665297     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/0969-8051(95)02088-8     Document Type: Article

References (43)

1. Corbett T. H., Griswold D. P. Jr., Roberts B. J., Peckham J. C. and Schabel F. M. Jr. (1975) Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure. Cancer Res. 35, 2434-2439.
2. Danenberg P. V. (1977) Thymidylate synthetase - a target enzyme in cancer chemotherapy. Biochim, Biophys. Acta 473, 73-92.
3. Diasio R. B. and Harris B. E. (1989) Clinical pharmacology of 5-fluorouracil. Clin. Pharmacokinet. 16, 215-237.
4. Dimitrikopoulou A., Strauss L. G., Clorius J. H., Ostertag H., Schlag P., Heim M., Oberdorfer F., Helus F., Haberkorn U. and van Kaick G. (1993) Studies with positron emission tomography after systemic administration of fluorine-18-uracil in patients with liver metastases from colorectal carcinoma. J. Nud.Med. 34, 1075-1081.
5. El-Tahtawy A. and Wolf W. (1991) In vivo measurements of intratumoral metabolism, modulation and pharmacokinetics of 5-fluorouracil, using F nuclear magnetic resonance spectroscopy. Cancer Res. 51, 5806-5812.
6. Finan P. J., Chisholm E. M., Woodhouse L. and Giles G. R. (1987) The relationship between plasma pharmacokinetics and tissue metabolites of 5-fluorouracil (5-FU) in patients with colorectal cancer. Eur. J. Surg. Oncol. 13, 349-353.
7. 19F nuclear magnetic resonance spectroscopy. Cancer Res. 51, 5770-5773.
8. Harris B. E., Song R., Soong S., and Diasio R. B. (1990) Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res. 50, 197-201.
9. Houyau P., Gay C., Chatelut E., Canal P., Roché H. and Milano G. (1993) Severe fluorouracil toxicity in a patient with dihydropyrimidine dehydrogenase deficiency. J. Nat. Cancer Inst. 85, 1602-1603.
10. 19F nuclear magnetic resonance spectroscopy, for patients receiving chemotherapy with or without methotrexate pretreatment. Cancer Res. 48, 1680-1688.
11. 19F-NMR for monitoring 5-fluorouracil chemotherapy. J. Cancer Res. Clin. Oncol. 113, 546.
12. Klohs W. D. and Steinkampf R. W. (1988) Possible link between the intrinsic drug resistance of colon tumors and a detoxification mechanism of intestinal cells. Cancer Res. 48, 3025-3030.
13. 18F]Fluorouracil - The problem of metabolites in tissue. J. Lab. Comp. Radiopharm. 35, 565-566.
14. 19F MRS studies of fluoropyrimidine chemotherapy: A review. NMR Biomed. 1, 1-9.
15. McSheehy P. M. J., Prior M. J. W. and Griffiths J. R. (1989) Prediction of 5-fluorouracil cytotoxicity towards the Walker carcinosarcoma using peak integrals of fluoronucleotides measured by MRS in vivo. Br. J. Cancer 60, 303-309.
16. Peters G. J., Lankelma J., Kok R. M., Noordhuis P., Van Groeningen C. J., Van der Wilt C. L., Meyer S. and Pinedo H. M. (1993b) Prolonged retention of high concentrations of 5-fluorouracil in human and murine tumors as compared with plasma. Cancer Chemother. Pharmacol. 31, 269-276.
17. Peters G. J. and Rustum Y. M. (1993) Novel approaches to selective treatments of human solid tumors: Laboratory and clinical correlation. Ann. Oncol. 4, 277-281.
18. Peters G. J., Schornagel J. H. and Milano G. A. (1993a) Clinical pharmacokinetics of anti-metabolites. Cancer Surv. 17, 123-156, and references cited therein.
19. Peters G. J., Van der Wilt C. L. and Van Groeningen C. J. (1994a) Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase. Eur. J. Cancer 30A, 1408-1411.
20. Peters G. J., Van der Wilt C. L., Van Groeningen C. J., Smid K., Meijer S. and Pinedo H. M. (1994b) Thymidylate synthase inhibition after administration of fluorouracil with or without leucovorin in colon cancer patients: Implications for treatment with fluorouracil. J. Clin. Oncol. 12, 2035-2042.
21. Peters G. J., van Dijk J., Nadal J. C., van Groeningen C. J., Lankelma J. and Pinedo H. M. (1987) Diurnal variation in the therapeutic efficacy of 5-fluorouracil against murine colon cancer. In vivo 1, 113-118.
22. Peters G. J. and Van Groeningen C. J. (1991) Clinical relevance of biochemical modulation of 5-fluorouracil. Ann. Oncol. 2, 469-480.
23. Pinedo H. M. and Peters G. J. (1988) Fluorouracil: Biochemistry and pharmacology. J. Clin. Oncol. 6, 1653-1664.
24. Presant C. A., Wolf W., Waluch V., Wiseman C., Kennedy P., Blayney D. and Brechner R. R. (1994) Association of intratumoral pharmacokinetics of fluorouracil with clinical response. Lancet 343, 1184-1187.
25. Price P. and Griffiths J. (1994) Tumour pharmacokinetics? We do need to know. Lancet 343, 1174-1175.
26. 19F NMR spectroscopy of the antimetabolites 5-fluorouracil and its analogues. Biochem. Pharmacol. 39, 857-863.
27. Ratain M. J., Shilsky R. L., Conley B. and Egorin M. J. (1990) Pharmacodynamics in cancer therapy. J. Clin. Oncol. 8, 1739-1753.
28. 18F)fluorouracil in sensitive versus resistant lymphocytic leukemia in mice. Cancer Res. 37, 2306-2308.
29. Sigurdson E. R. and Cohen A. M. (1991) Commentary on "The applications of PET in clinical oncology." J. Nucl.Med. 32, 649-650.
30. 19F-NMR. Br. J. Cancer 50, 113-117.
31. Strauss L. G. and Conti P. S. (1991) The applications of PET in clinical oncology. J. Nucl. Med. 32, 623-648.
32. Swain S. M., Lippman M. E., Egan E. F., Drake J. C., Steinberg S. M. and Allegra C. J. (1989) Fluorouracil and high dose leucovorin in previously treated patients with metastatic breast cancer. J. Clin. Oncol. 7, 890.
33. Valeriote F. and Santelli G. (1984) 5-Fluorouracil (Fura). Pharmacol. Ther. 24, 107-132.
34. Van der Wilt C. L., Pinedo H. M., Smid K. and Peters G. J. (1992) Elevation of thymidylate synthase following 5-fluorouracil treatment is prevented by the addition of leucovorin in murine colon tumors. Cancer Res. 52, 4922-4928.
35. Van der Wilt C. L., Visser G. W. M., Braakhuis B. J. M., Wedzinga R., Noordhuis P., Smid K. and Peters G. J. (1993) In vitro antitumor activity of cis- and trans-5-fluoro-5,6-dihydro-6-alkoxy-uracils; effects on thymidylate synthesis, Br. J. Cancer 68, 702-707.
36. Van Groeningen C. J., Pinedo H. M., Heddes J., Kok R. M., De Jong A. P. J. M., Wattel E., Peters G. J. and Lankelma J. (1988) Pharmacokinetics of 5-fluorouracil assessed with a sensitive mass spectrometric method in patients during a dose escalation schedule. Cancer Res. 48, 6956-6961.
37. Visser G. W. M., Boele S., v. Halteren B. W., Knops G. H. J. N., Herscheid J. D. M., Brinkman G. A. and Hoekstra A. (1986) Mechanism and stereo-chemistry of the fluorination of uracil and cytosine using fluorine and acetyl hypofluonte. J. Org. Chem. 51, 1466-1471.
38. 18F-labelled 5-fluorouracil and a reevaluation of its use as a prognostic agent. Eur. J. Nucl. Med. 15, 225-229.
39. 18F]-5-fluorouracil in mice: Effects of route of administration, strain, tumour and dose. Cancer Chemother. Pharmacol. 26, 205-209.
40. Visser G. W. M., Wedzinga R., Klok R. P. and Herscheid J. D. M. (1994) Fluorinated pyrimidines: Part 4. Synthesis, properties and stereochemical conversion of the cis and trans isomers of 6-alkoxy-5-fluoro-5,6-dihydrouracils. J. Chem. Soc. Perkin Trans. 2, 231-236.
41. 19F NMR spectroscopic pharmacokinetics in tumor-bearing humans and rabbits. Proc. Nad. Acad. Sci. USA 87, 492-196.
42. Zhang R., Barnes S. and Diasio R. B. (1991) Disposition and metabolism of 2-fluoro-β-alanine conjugates of bile acids following secretion into bile. Biochim. Acta 1096, 179-186.
43. Zhang R., Soong S. J., Liu T., Barnes S. and Diasio R. B. (1992) Pharmacokinetics and tissue distribution of 2-fluoro-β-alanine in rats: Potential relevance to toxicity pattern of 5-fluorouracil. Drug Metab. Dispos. 20, 113-119.